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Available online 26 November 2015The Genea043 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated human feeders. The line showed pluripotent cell morphology
and genomic analysis veriﬁed a 46, XY karyotype and male allele pattern through traditional karyotyping,
CGH and STR analysis. Pluripotency of Genea043 was demonstrated with 92% of cells expressing Nanog, 95%
Oct4, 61% Tra1–60 and 99% SSEA4, a PluriTest Pluripotency score of 31.74, Novelty score of 1.2 and Alkaline Phos-
phatase activity. The cell line was negative for Mycoplasma and any visible contamination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Resource tableName of stem cell line Genea043 (Alternate ID: SIVF043)Kstitution Genea biocells
Se
Person who created
resourceBiljana DumevskaD
ontact person and
emailbiljana.dumevska@geneabiocells.comState archived/stock
dateMarch, 2009Sirigin Human embryos
ype of resource Derived human embryonic stem cell line
ub-type Human pluripotent cell line
ey marker
expressionNanog, Oct4, Tra1–60, and SSEA4uthentication Identity and purity of cell line conﬁrmed
(Figures 1–2, Tables 1–2 below)nk to related
literature (direct
URL links and full
references)(Laurent et al., 2011)
http://www.ncbi.nlm.nih.gov/pubmed/
?term=21211785formation in public
databasesNational Institutes of Health (NIH) registered
NIHhESC-13-0232
UK Stem Cell Bank (UKSCB) registered SCSC14–40
SNP Data GEO accession numbers
GSM638445thical approval Obtained from the Genea Ethics Committee on 21
February 2001 under the Australian National Health
andMedical Research Council (NHMRC) licence 309703midt).
. This is an open access article under2. Resource DetailsthDate of derivatione CC BY-NC-ND licFebruary 2009aryotype 46, XY — no abnormalities detected
x Male
luripotent YES — by Alkaline Phosphatase stain positivity, Nanog, Oct4,
Tra1–60, and SSEA4 staining and PluriTest
isease status Unaffected
erility The cell line is tested and found negative for Mycoplasma and
any visible contamination
bling lines
availableYES — GENEA042 (XX NIHhESC-13-0231, SCSC14–40)3. Materials and methods
3.1. Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was bisected and both
ICM and trophectoderm were plated onto mitomycin C inactivated De-
troit 510 HFF human feeders (plated 90,000 cells 1 well of 4 well —
47,368 cells/cm2) in 20% Knock out serum in standard hESC cultureme-
dium (Amit et al., 2000) with 20 ng/mL Fgf2. CGH, karyotyping and STR
proﬁling was performed at the ﬁrst cryobanking step from ICM out-
growthsmaintained on feeders. Alkaline Phosphatase staining was per-
formed on feeders. Cells were then enzymatically passaged as single
cells in M2 pluripotent cell maintenance medium (Genea Biocells) and
genetic analysis repeated, immunoﬂuorescent pluripotent marker
staining, PluriTest, teratoma and sterility testing performed.ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Karyotyping: Passage 4; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred to
Sydney IVF's (nowGenea) diagnostic cytogenetics laboratory for prep-
aration of metaphase spreads and cytogenetic analysis by G-banding.
Aminimum of 15metaphase cells were examined, of which a full kar-
yotype or chromosome counts was performed for 5 and 10 of the
metaphases respectively.
2. Comparative Genomic Hybridization (CGH) based chromosomal
analysis: Passage 10 (8 on feeders, 2 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and
duplications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner CFig. 1. Morphology and karyotype of Genea043. A) Brightﬁeld (passage 1) growing on
human inactivated feeders. B) Alkaline phosphatase activity (passage 4) on human
inactivated feeders. C) Karyotypic analysis passage 4 showing 46, XY normal, male
karyotype.and analysed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).
3. DNA Proﬁling: Passage 3; DNA ‘ﬁngerprinting’ was performed
using the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied
Biosystems #4322288) to provide permanent genetic identiﬁcation of
the cell lines https://www.thermoﬁsher.com/order/catalog/product/
4322288.
3.3. Pluripotency assessment
1. Alkaline Phosphatase: Passage 4; Genea043 grown on feeders
were stained as per manufacturers protocol using the Merck
Millipore Alkaline Phosphatase Detection Kit (SCR004).
2. Immunoﬂuorescence: Passage 10 (8 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560,483 1:200;
Oct4 #560,217 1:150: Tra1–60 #560,121 1:150; SSEA4 #560,308
1:200 (all BD Pharmingen:). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
3. PluriTest: Passage 11 (8 on feeders, 3 enzymatic); RNAwas collected
and subjected to a PluriTest, a bioinformatics assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
3.4. Sterility testing
1. Mycoplasma: Passage 13; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR.
2. Microbial contamination: Testing was performed in conjunction
with our QC measures. Cells were thawed and cultured in 7 mL anti-
biotic free medium (Genea Biocells M2 medium) for 2–3 days at
37 °C. A clear solution at ~48–72 h indicated lack of bacterial, fungal
or yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
4. Veriﬁcation and authentication
4.1. Ethics/consents
Ethics approval for the project (‘Development of human embryonic
stem cells from excess ART embryos’) was obtained from the Genea
Ethics Committee on 21 February 2001. Excess ART embryos were
fully consented for stem cell derivation by all responsible people
through an informed consent process (signed de-identiﬁed consent
form can be provided upon request). Donors have received no payment
or ﬁnancial beneﬁts for their donation. Genea043 has been derived from
a donated, fully commercially consented human embryo, originally
created by assisted reproduction technology (ART) for the purpose of
procreation, under Australian National Health and Medical Research
Council (NHMRC) licence 309703. This licence was issued to GENEA
on 16 April 2004. More information about the licence can be obtained
from the NHMRC webpage at http://www.nhmrc.gov.au/health-
ethics/human-embryos-and-cloning/database-licences-authorising-
use-excess-art-embryos.Table 1
CGH analysis summary of Genea043 (Passage 10, 2 enzymatic) reporting a male cell line
and no abnormalities detected.
CGH summary
Sample name Genea043p10_2
Date reported 20th August 2013
Hybridisation balance A balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes N400 kb were detected
Interpretation Male cell line — no abnormalities detected
Fig. 2. Pluripotency validation of Genea043. A) Immunoﬂuorescent staining (10×) of pluripotent cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), Passage 10 (2
enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest pluripotency (left) and novelty (right) scores with Genea043 (Passage 11, 3 enzymatic) outlined in black.
Table 2
STR proﬁle of Genea043 (Passage 3), demonstrating male allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
SIVF043_p3 13,14 30,30.2 8,10 12 16,17 7,8 11,13 11 16,18 13,14 14,17 8 15,16 11,13 23
154 B. Dumevska et al. / Stem Cell Research 16 (2016) 152–1544.2. Morphology
The derived stem cell line, Genea043, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli (Figs. 1A/B).
4.3. Genetic analysis
The cell line has been karyotyped (Fig. 1C, Supplementary Fig. 1) and
tested by CGH (Table 1, Supplementary Fig. 2), which demonstrated 46,
XY karyotype, consistent with original derivation. Analysis of STR
markers showed Allele pattern consistent with male genotype Table 2,
Supplementary Fig. 3).
4.4. Disease status
Unaffected.
4.5. Pluripotency
GENEA043 is pluripotent by:
1. Alkaline Phosphatase stain positivity (Fig. 1B)
2. Immunoﬂuorescence with 92% Nanog positive, 95% Oct4 positive,
61% Tra1–60 positive, and 99% SSEA4 positive (Fig. 2A, quantiﬁed
in 2B)3. PluriTest with a 31.74 Pluripotency score and 1.2 Novelty score
(Fig. 2C).
4.6. Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.11.010.
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